{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '19.', 'Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer', 'without previous chemotherapy. N Engl J Med 2013; 368: 138-148.', '20.', 'Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate', 'cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.', '21.', 'Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone', 'plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.', '22.', 'James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid, or', 'both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results', 'from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2015.', '23.', 'Sweeney CJ, Chen YH, Carducci M et al. Chemohormonal Therapy in Metastatic', 'Hormone-Sensitive Prostate Cancer. N Engl J Med 2015; 373: 737-746.', '24.', 'Gravis G, Fizazi K, Joly F et al. Androgen-deprivation therapy alone or with docetaxel', 'in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase', '3 trial. Lancet Oncol 2013; 14: 149-158.', '25.', 'Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to', 'antiandrogen therapy. Nat Med 2004; 10: 33-39.', '26.', 'Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer:', 'directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-', '8261.', '27.', 'Loriot Y, Bianchini D, Ileana E et al. Antitumour activity of abiraterone acetate', 'against metastatic castration-resistant prostate cancer progressing after docetaxel and', 'enzalutamide (MDV3100). Ann Oncol 2013; 24: 1807-1812.', '28.', 'Noonan KL, North S, Bitting RL et al. Clinical activity of abiraterone acetate in', 'patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.', 'Ann Oncol 2013; 24: 1802-1807.', '29.', 'Schrader AJ, Boegemann M, Ohlmann CH et al. Enzalutamide in castration-resistant', 'prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014; 65: 30-36.', '30.', 'Bianchini D, Lorente D, Rodriguez-Vida A et al. Antitumour activity of enzalutamide', '(MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated', 'with docetaxel and abiraterone. Eur J Cancer 2014; 50: 78-84.', '31.', 'Suzman DL, Luber B, Schweizer MT et al. Clinical activity of enzalutamide versus', 'docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.', 'Prostate 2014; 74: 1278-1285.', '32.', 'Badrising S, van der Noort V, van Oort IM et al. Clinical activity and tolerability of', 'enzalutamide (MDV3100) in patients with metastatic, castration-resistan prostate cancer who', 'progress after docetaxel and abiraterone treatment. Cancer 2014; 120: 968-975.', '33.', 'Cheng HH, Gulati R, Azad A et al. Activity of enzalutamide in men with metastatic', 'castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or', 'docetaxel. Prostate Cancer Prostatic Dis 2015; 18: 122-127.', '34.', 'Azad AA, Eigl BJ, Murray RN et al. Efficacy of enzalutamide following abiraterone', 'acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur', 'Urol 2015; 67: 23-29.', '35.', 'Robinson D, Van Allen EM, Wu YM et al. Integrative clinical genomics of advanced', 'prostate cancer. Cell 2015; 161: 1215-1228.', '79(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '36.', 'Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral', 'androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.', 'Cancer Res 2008; 68: 4447-4454.', '37.', 'Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting', 'adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;', '66: 2815-2825.', '38.', 'Drake JM, Graham NA, Lee JK et al. Metastatic castration-resistant prostate cancer', 'reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc', 'Natl Acad SciUS A 2013; 110: E4762-4769.', '39.', 'Hu R, Lu C, Mostaghel EA et al. Distinct transcriptional programs mediated by the', 'ligand-dependent full-length androgen receptor and its splice variants in castration-resistant', 'prostate cancer. Cancer Res 2012; 72: 3457-3462.', '40.', 'Joseph JD, Lu N, Qian J et al. A clinically relevant androgen receptor mutation confers', 'resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov', '2013; 3: 1020-1029.', '41.', 'Mehra R, Kumar-Sinha C, Shankar S et al. Characterization of bone metastases from', 'rapid autopsies of prostate cancer patients. Clin Cancer Res 2011; 17: 3924-3932.', '42.', 'Taylor BS, Schultz N, Hieronymus H et al. Integrative genomic profiling of human', 'prostate cancer. Cancer Cell 2010; 18: 11-22.', '43.', 'Yeh S, Lin HK, Kang HY et al. From HER2/Neu signal cascade to androgen receptor', 'and its coactivators: a novel pathway by induction of androgen target genes through MAP', 'kinase in prostate cancer cells. Proc Natl Acad Sci U S A 1999; 96: 5458-5463.', '44.', 'Arora VK, Schenkein E, Murali R et al. Glucocorticoid receptor confers resistance to', 'antiandrogens by bypassing androgen receptor blockade. Cell 2013; 155: 1309-1322.', '45.', 'Antonarakis ES, Lu C, Wang H et al. AR-V7 and resistance to enzalutamide and', 'abiraterone in prostate cancer. N Engl J Med 2014; 371: 1028-1038.', '46.', 'Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent developments', 'and future challenges. Cancer Metastasis Rev 2014; 33: 641-655.', '47.', 'Chuu CP, Kokontis JM, Hiipakka RA et al. Androgens as therapy for androgen', 'receptor-positive castration-resistant prostate cancer. J Biomed Sci 2011; 18: 63.', '48.', 'Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in', 'athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci U S', 'A 1996; 93: 11802-11807.', '49.', 'Zhau HY, Chang SM, Chen BQ et al. Androgen-repressed phenotype in human', 'prostate cancer. Proc Natl Acad Sci U S A 1996; 93: 15152-15157.', '50.', 'Chuu CP, Hiipakka RA, Fukuchi J et al. Androgen causes growth suppression and', 'reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated', 'phenotype in athymic mice. Cancer Res 2005; 65: 2082-2084.', '51.', 'Maffini MV, Geck P, Powell CE et al. Mechanism of androgen action on cell', 'proliferation: AS3 protein as a mediator of proliferative arrest in the rat prostate.', 'Endocrinology 2002; 143: 2708-2714.', '52. Kokontis JM, Lin HP, Jiang SS et al. Androgen suppresses the proliferation of', 'androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2,', 'CyclinA, and Skp2. PLoS One 2014; 9: e109170.', '80(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}